US/UK/Canada

Share

Links

Quotes

In the past, resistance mechanisms were usually thought of as static. Our study demonstrates, conversely, that a binary designation of resistance may oversimplify cancer’s true biology. These genetic mutations can fluctuate over time, and some patients can harbor more than one mutation.
Zofia Piotrowska, MD, lead author of the study
In an era where cancer treatment is increasingly personalized to the biology of each individual patient, our findings highlight the importance of molecular testing and the need for improved, noninvasive methods for serial testing.
Zofia Piotrowska, MD
In the past year, the Vice President’s moonshot initiative has brought critical attention to the need for greater collaboration and innovation in cancer research, and we are invigorated at the prospect of radiation oncology being an instrumental component of future progress. Moving forward, we must maintain the focus on advancing both the science and practice of cancer care while aligning our efforts to move Congress to authorize the $700 million requested by the President for cancer research initiatives. Substantial, predictable financial support is essential to sustain the fight to eradicate cancer.
Bruce G. Haffty, MD, FASTRO, past Chair of ASTRO’s Board of Directors
The goal of ASTRO’s 2016 Annual Meeting is to highlight the latest scientific and technological advances while emphasizing the importance of radiation oncology in providing value to cancer patients through cure and palliation.
ASTRO President David C. Beyer, MD, FASTRO
Pick a time period -
Tags ( Active)

ROI awards grants to Drs. David Sher and Anand Shah for projects to examine the comparative value of radiation therapy

The Radiation Oncology Institute (ROI) has selected David J. Sher, MD, MPH, an associate professor in the Department of Radiation Oncology at the University of Texas—Southwestern Medical Center in Dallas, and Anand Shah, MD, MPH, a post-doctoral residency fellow in the Department of Radiation Oncology at Columbia University Medical Center in New York to receive grants for their projects to examine the comparative value of radiation therapy (RT), in response to ROI’s Request for Proposals (RFP) issued earlier this year. Sher’s project is titled “Comparative value of transoral surgery and

10 years of data reveals excellent, sustained local control with minimal side effects for medically inoperable, early stage lung cancer patients

Data from patients that received high-dose rate stereotactic body radiotherapyAnalysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control, 79 percent of tumors, for medically inoperable, early stage lung cancer patients treated with SBRT from 2003 to 2012, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The Symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International

Lung cancer patients with minimally invasive adenocarcinoma have comparable 97.7 percent 5-year survival rate as patients with adenocarcinoma in-situ

Lung cancer patients with minimally invasive adenocarcinoma (MIA) have similar, positive five-year disease-free survival (DFS) and overall survival (OS) rates as patients with adenocarcinoma in-situ (AIS), according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The Symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago Medicine. Lung adenocarcinoma accounts for 60

Medicare costs analysis indicates need for decreasing use of biopsies as diagnosis tool for lung cancer

More than 43 percent of $38.3 million in diagnostic costs attributed to biopsies for patients with ultimately negative lung cancer diagnosisBiopsies were found to be the most costly tool prescribed in lung cancer diagnosis, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The Symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago Medicine. The study examined the

Molecular tumor markers could reveal new therapeutic targets for lung cancer treatment

Study examined more than 600 small cell lung cancer and lung neuroendocrine tumorsAnalysis of 607 small cell lung cancer (SCLC) lung tumors and neuroendocrine tumors (NET) identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The Symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the

Patients at high-risk for lung cancer are more likely to receive screening when primary care provider is familiar with guideline recommendations

Results of more than 200 primary care providers indicate knowledge gapPatients at high-risk for developing lung cancer are more likely to receive low-dose computed tomography (LDCT) screening when their primary care provider is familiar with guideline recommendations for LDCT screening for lung cancer, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The Symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung

Post-operative radiation therapy improves overall survival for patients with resected non-small cell lung cancer

According to analysis of more than 2,100 patients treated from 2004 to 2006Patients who received post-operative radiation therapy (PORT), radiation therapy after surgery, lived an average of four months longer when compared to the patients who had the same disease site, tumor histology and treatment criteria and who did not receive PORT, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The Symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the

Leading lung cancer research to be presented at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

What: The 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago, will provide a clinically relevant, multidisciplinary update on the scientific progress in treating thoracic malignancies. The symposium brings together physician specialists and practicing clinicians of the multidisciplinary care team to discuss the evolving management of thoracic cancers. The symposium will

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media